|
| Code | Diagnosis | Comment | Score |
| anonymous | Cholangiocarcinoma (100%) | nil | 100 |
| anonymous | Cholangiocarcinoma | nil | 100 |
| anonymous | ADENOCARCINOMA, in favour of primary cholangiocarcinoma, to exclude metastatic adenocarcinoma | To perform immunohistochemical stains: CK7/CK20, CK19 (typically positive for cholangiocarcinoma), TTF-1 (pulmonary adenocarcinoma), CDX2 (gastrointestinal tract adenocarcinoma) and PSA (prostate adenocarcinoma) | 100 |
| anonymous | Cholangiocarcinoma | nil | 100 |
| anonymous | CHOLANGIOCARCINOMA, with bile duct adenomatous hyperplasia in the background consistent with recurrent pyogenic cholangitis or hepatolithiasis. 100% | HepPar-1 to exclude heatocellular ca component in the crushed areas. Metastases, RPC and stones can be excluded by clinical correlation. | 100 |
| anonymous | Adenocarcinoma, favors cholangiocarcinoma.(100%) | Background cholangitis needs to be considered. | 100 |
| anonymous | Liver - cholangiocarcinoma 100% | nil | 100 |
| anonymous | Adenocarcinoma, favouring cholangiocarcinoma (100%) | nil | 100 |
| anonymous | Cholangiocarcinoma 100% | nil | 100 |
| anonymous | Cholangiocarcinoma. | Confirm with Immunohistochemistry. | 100 |
| anonymous | Liver - Intrahepatic cholangiocarcinoma | nil | 100 |
| anonymous | Cholangiocarcinoma | nil | 100 |
| anonymous | Adenocarcinoma, favour cholangiocarcinoma (100% probability) | nil | 100 |
| anonymous | Cholangiocarcinoma (100%) | nil | 100 |
| anonymous | LIVER - ADENOCARCINOMA, favour cholangiocarcinoma (100%) | Suggest immunohistochemical staining for CK7, CK20 and correlate with clinical findings. | 100 |